Drugs News and Research

RSS

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.

7 Dec 2014

Three-drug combination produces better results in multiple myeloma patients

In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.

7 Dec 2014

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Orexo announces positive results from ISTART/006 study

Orexo US, Inc. announced results from the ISTART/006 study, being presented today at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry in Aventura, Florida, USA.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Drugs we release into the environment significantly affect plant growth, study reveals

The drugs we release into the environment are likely to have a significant impact on plant growth, a new study has revealed.

6 Dec 2014

Study suggests Golgi as potential drug target for Alzheimer's treatment

Alzheimer's disease (AD) progresses inside the brain in a rising storm of cellular chaos as deposits of the toxic protein, amyloid-beta (Aβ), overwhelm neurons. An apparent side effect of accumulating Aβ in neurons is the fragmentation of the Golgi apparatus, the part of the cell involved in packaging and sorting protein cargo including the precursor of Aβ. But is the destruction the Golgi a kind of collateral damage from the Aβ storm or is the loss of Golgi function itself part of the driving force behind Alzheimer's? This was the question for Yanzhuang Wang, Gunjan Joshi, and colleagues at the University of Michigan, Ann Arbor, as they set out to uncover the mechanism damaging the Golgi, using a transgenic mouse and tissue culture models of AD to look at what was going on.

6 Dec 2014

Research findings may lead to new ways to thwart drug resistance

Penicillin, the wonder drug discovered in 1928, works in ways that are still mysterious almost a century later. One of the oldest and most widely used antibiotics, it attacks enzymes that build the bacterial cell wall, a mesh that surrounds the bacterial membrane and gives the cells their integrity and shape. Once that wall is breached, bacteria die -- allowing us to recover from infection.

6 Dec 2014

University of Utah professor develops MORE intervention program for chronic pain patients

How can people who are dependent on prescription opioids reduce their cravings? Learn to enjoy other aspects of their lives.

6 Dec 2014

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

An international research collaborative has determined that a promising anti-malarial compound tricks the immune system to rapidly destroy red blood cells infected with the malaria parasite but leave healthy cells unharmed. St. Jude Children's Research Hospital scientists led the study, which appears in the current online early edition of the Proceedings of the National Academy of Sciences.

5 Dec 2014

Survey: Rising health care costs prompt local governments to make changes to plans, strategies

Although health care costs have slowed recently, rising costs over the last decade have prompted many local governments to make changes to their plans and strategies, according to a new nationwide survey by the Center for State and Local Government Excellence.

5 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

University of Miami researcher reveals association between 'salience processing' and brain disorders

How does the brain determine what matters? According to a new scientific article, a brain structure called the insula is essential for selecting things out of the environment that are "salient" for an individual, and dysfunction of this system is linked to brain disorders such as autism, psychosis and dementia.

5 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc., has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide.

5 Dec 2014

Simple treatments for Ebola patients not given sufficient priority

The widespread misconception that there are no proven treatments for Ebola virus disease has meant that simple treatments – especially intravenous fluids and electrolytes, which could reduce the number of deaths caused by the virus – have been neglected, according to a new Comment, published in The Lancet.

5 Dec 2014

Two medical imaging techniques could predict effectiveness of TB drugs

Two medical imaging techniques, called positron emission tomography (PET) and computed tomography (CT), could be used in combination as a biomarker to predict the effectiveness of antibiotic drug regimens being tested to treat tuberculosis (TB) patients, according to researchers at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Dec 2014

Researchers evaluate barriers to coordinating 'transitional care' of older adults

In what is believed to be the first interview-style qualitative study of its kind among health care providers in the trenches, a team led by a Johns Hopkins geriatrician has further documented barriers to better care of older adults as they are transferred from hospital to rehabilitation center to home, and too often back again.

5 Dec 2014

Three IU researchers receive $2.1 million to develop computational biology models of liver toxicity

Three Indiana University professors have received $2.1 million to develop a computational model of acetaminophen-induced liver failure -- the leading cause of liver failure in the United States -- by using advanced microscopic and computational technologies that allow scientists to see into the liver of a living animal.

5 Dec 2014

Drugs News and Research

Novel treatments show promising results in patients with different hematologic disorders

Three-drug combination produces better results in multiple myeloma patients

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Orexo announces positive results from ISTART/006 study

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Drugs we release into the environment significantly affect plant growth, study reveals

Study suggests Golgi as potential drug target for Alzheimer's treatment

Research findings may lead to new ways to thwart drug resistance

University of Utah professor develops MORE intervention program for chronic pain patients

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

Survey: Rising health care costs prompt local governments to make changes to plans, strategies

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

University of Miami researcher reveals association between 'salience processing' and brain disorders

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Simple treatments for Ebola patients not given sufficient priority

Two medical imaging techniques could predict effectiveness of TB drugs

Researchers evaluate barriers to coordinating 'transitional care' of older adults

Three IU researchers receive $2.1 million to develop computational biology models of liver toxicity

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News